The Phase II portion is seeking to establish safety and efficacy of the company’s HER2 breast cancer therapy in combination ...

A promising new mRNA-based vaccine for pancreatic cancer has shown potential in reducing the recurrence of the disease post-surgery. MSK's phase 1 cli ...

Tremfya could become the first IL-23 inhibitor with fully subcutaneous induction and maintenance options in the treatment of ...

The field of central nervous system (CNS) drug development is awash with activity. And major new centres of research are ...

NEWARK, CA / ACCESS Newswire / February 21, 2025 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today reported financial results for the fourth quarter and full year ended ...

The revolutionary BiVACOR heart device was moved to Phase 2 of FDA trials after success in five human patients.

Chime Biologics, a leading global CDMO that enables its partners' success in biologics, today announced its continued ...

Net product sales of CAPLYTA were $680.5 million for the full year 2024. This represents an increase of 47% compared to 2023.

Sellas Life Sciences has reported the multicentre Phase IIa trial data of a highly selective cyclin-dependent kinase 9 (CDK9) ...